Inquiry

Neutral Non-fucosylated HMO Production Service

Neutral non-fucosylated HMOs involve a wide range of research fields, including infant intestinal flora balance, improving immunity, food processing, etc., and have high market development potential. CD BioGlyco has always been committed to cutting-edge scientific research and product development in the field of nutrition, providing you with one-stop production services of neutral non-fucosylated HMO.

Relationship Between Neutral Non-fucosylated HMOs and HMOs

Human milk oligosaccharides (HMOs), functional oligosaccharides with diverse structures, have substantially positive effects on neonatal development, the nervous system, digestive system, immune system, etc. At present, more than 200 kinds of HMOs have been identified. According to different modified genes, HMOs can be divided into three types: neutral fucosylated HMOs, neutral non-fucosylated HMOs, and sialylated acidic HMOs, of which the proportion of neutral HMOs is up to 75%. Neutral non-fucosylated HMO has many potential applications in infant milk powder, dietary supplements, and healthy food for the elderly and lactating women.

Biological Function of Neutral Non-fucosylated HMOs

Neutral non-fucosylated HMOs include lactose (Lac), lacto-N-tetraose (LNT), lacto-N-biose (LNB), N-acetyllactosamine (LacNAc), lacto-N-neotetraose (LNnT) and other oligosaccharides. It has a variety of biological activities, some of which are listed as follows:

Nutrition source

Promote the growth and development of infants.

Digestive system

Neutral non-fucosyl HMOs help to absorb minerals and regulate the balance of intestinal flora. For example, LNB is a highly specific natural prebiotic for Bifidobacteria and LacNAc is a constituent of glycoproteins and glycolipids in the gastrointestinal tract.

Immune regulation function

LNnT and its derivatives can stimulate type II immunity by increasing the number of Grl cells and antigen-presenting cells.

Food Manufacturing

Lac reacts with amino compounds such as protein, peptide, or amino acid under heating conditions to produce caramel color or brown flavor, which can be used in the production of baked food and flavoring products.

Neutral Non-fucosylated HMO Production Service at CD BioGlyco

CD BioGlyco has accumulated a variety of production methods, including chemical synthesis, separation and purification, whole-cell biotransformation (fermentation), enzyme catalysis (isolated enzyme biotransformation), and chemoenzymatic methods. The neutral non-fucosylated HMOs we have produced include but are not limited to the types listed in the following table, and we are also expanding the production of new types of neutral non-fucosylated HMOs.

Enzymatic Synthesis: A highly specific and efficient method that utilizes isolated enzymes, such as glycosyltransferases, to build the oligosaccharide chain step-by-step. This approach is ideal for producing specific, high-purity structures on a smaller scale and is a cornerstone of our service.
Microbial Fermentation: The most robust and scalable method for large-volume production. We engineer microbial strains to synthesize the target HMOs in a cost-effective and highly reproducible manner. This is the preferred method for commercial-scale projects in the food and dietary supplement industries.
Chemo-enzymatic Synthesis: A hybrid approach combining the strengths of chemical and enzymatic synthesis to produce complex structures efficiently. This method provides flexibility and control, allowing us to develop novel or difficult-to-synthesize HMO variants.

We provide clients with the following neutral non-fucosylated HMO production service.

Workflow

Workflow for neutral non-fucosylated HMO production. (CD BioGlyco)

Publication Data

DOI: 10.3390/nu12030826

Journal: Nutrients

IF: 5.0

Published: 2020

Results: Using high-performance liquid chromatography (HPLC)-mass spectrometer (MS) to analyze 23 neutral HMOs and defining maternal Secretor/Lewis phenotypes via 2′-fucosyllactose (2′-FL) and lacto-N-fucopentaose (LNFP)-II concentrations, it found 76.7% of mothers were Se+Le+, 17.2% Se-Le+, 4.3% Se+Le-, and 1.7% Se-Le-. Secretor phenotype determined specific HMOs (e.g., 2′-FL was undetectable in non-Secretors, who had higher non-fucosylated HMOs like LNT&LNnT), most HMOs decreased with lactation (except 3′-FL and LDFT). Maternal factors (age, allergic history, pre-pregnancy BMI, parity, delivery mode) and infant factors (gestational age, gender) correlated with specific HMO concentrations, and while Secretor/non-Secretor status didn't affect infant growth, certain HMOs linked to infant length gain and disease status. It concluded Secretor phenotype and lactation stage are key neutral HMO influencers, with other maternal/infant traits affecting specific HMOs.

Advantages

Seasoned expertise

Our team consists of Ph.D.-level scientists with decades of collective experience in glycobiology and bioprocess engineering. This deep knowledge allows us to tackle the most complex production challenges and provide expert guidance throughout your project.

Scalable and cost-effective

With expertise in both small-scale enzymatic synthesis and large-scale microbial fermentation, we can seamlessly transition your project from the lab to commercial production.

Exceptional purity and quality

Our multi-stage purification and stringent quality control processes ensure that every batch of product meets the highest standards for purity, structural integrity, and consistency.

Applications

Functional foods and dietary supplements

Beyond infant formula, neutral non-fucosylated HMOs are being incorporated into adult dietary supplements and functional foods designed to support gut health, immune function, and overall well-being.

Probiotic and prebiotic research

These molecules serve as selective prebiotics, specifically feeding beneficial microbes. This makes them a crucial tool in research aimed at understanding and modulating the human microbiome.

Therapeutic development

HMOs may have direct therapeutic potential in treating a variety of conditions, including inflammatory bowel diseases, allergies, and certain infectious diseases, acting as anti-adhesive agents against pathogens.

Frequently Asked Questions

Customer Review

"The high-purity LNnT CD BioGlyco provided was critical for our in vitro studies. The team was highly responsive, knowledgeable, and the final product exceeded our expectations, allowing us to publish our findings faster than anticipated."

-K.S., Principal Investigator

"We required a large quantity of a specific non-fucosylated HMO for our new infant formula product research. CD BioGlyco not only delivered on time but also provided an excellent Certificate of Analysis. The consistency and quality of their product streamlined our production process and gave us full confidence in our final product."

- P.L., Director of R&D, Nutrition Company

"CD BioGlyco helped us select the best production method for our specific needs and provided expert advice on downstream applications. Their attention to detail and commitment to our project's success made them an ideal partner for our work."

- A.T., Senior Scientist, Pharmaceutical Development

Associated Services

HMO Analysis

We provide advanced analytical services to verify the structure, purity, and concentration of your HMO samples. This is an essential step for both quality control and fundamental research.

Fucosylated HMO Production

If your project requires fucosylated HMOs, such as 2'-fucosyllactose (2'FL) and 3-fucosyllactose (3FL), we provide a seamless transition to our specialized production services.

Glycan Microarray

Our glycan microarray is used to screen the binding of your HMOs to a wide range of proteins, cells, or pathogens, helping you understand their biological function and mechanism of action.

CD BioGlyco is the world's leading supplier of neutral non-fucosylated HMOs. We have achieved fruitful results in maternal and infant health research projects at home and abroad. If you are interested in our services, please contact us feel free.

Reference

Wang, M.; et al. Neutral human milk oligosaccharides are associated with multiple fixed and modifiable maternal and infant characteristics. Nutrients. 2020; 12: 826. (Open Access)

This service is for Research Use Only, not intended for any clinical use.